#	Pagina
attuale pagina	/open-h2020/projects/226369/index.html
-1	/open-h2020/projects/208225/index.html
-2	/open-h2020/projects/225234/index.html
-3	/open-h2020/projects/211572/index.html
-4	/open-h2020/projects/216819/results.html
-5	/open-h2020/projects/212244/results.html
-6	/open-h2020/projects/194094/deliverables.html
-7	/open-h2020/projects/194812/results.html
-8	/open-h2020/projects/202658/index.html
-9	/open-h2020/per-topic/tipping/list/index.html
-10	/open-h2020/projects/209761/results.html

Opendata, web and dolomites

NOVOBIOME-1 SIGNED

Development of a novel human derived probiotic species platform - Phase 1

Total Cost €

EC-Contrib. €

Partnership

Views

NOVOBIOME-1 project word cloud

Explore the words cloud of the NOVOBIOME-1 project. It provides you a very rough idea of what is the project "NOVOBIOME-1" about.

130 combines models commercialization probiotics novobiome functional play market fte anticipates first whereas innovative service anticipated 35 worldwide struggling probiotic segment customers million ngp track platform mainly healthy companies timeline winclove coming cultivation full moving ngps live tackle maximize formulations services generate generation attractive house origins leverages leader successful daily annum successfully 2018 positive cycle reached facilities human global sme substantially lbps limited grow manufacturing sustainable commercializing turnover instrument untapped clients flourishing dosages dutch company techniques intrinsic fee sold technological microbiota infrastructure 73 8m biotherapeutic radically fast b2b business provides 25 countries 14

Project "NOVOBIOME-1" data sheet

The following table provides information about the project.

Coordinator	WINCLOVE BV Organization address address: HULSTWEG 11 city: AMSTERDAM postcode: 1032 LB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2020
Duration (year-month-day)	from 2020-02-01 to 2020-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	WINCLOVE BV WINCLOVE BV Organization address address: HULSTWEG 11 city: AMSTERDAM postcode: 1032 LB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	coordinator	50˙000.00

Map

Project objective

The global probiotics market is flourishing and anticipated to grow substantially in the coming years due the highly promising application of next-generation probiotics (NGPs) as live biotherapeutic products (LBPs). Whereas traditional probiotics are mainly derived from non-human origins with limited positive effects, NGPs are human-derived and play a key role in a healthy microbiota. All major probiotic companies are now moving into this field, however they are struggling with product development due to the intrinsic properties of NGPs. As a result, no NGP products have successfully reached the market yet. NGP product development requires radically new techniques for cultivation and production. This untapped market segment is highly attractive for Winclove. To tackle this problem, Winclove is developing the NOVOBIOME platform – covering the full cycle of NGP product development. Winclove’s approach leverages its already functional in-house facilities and infrastructure and combines it with innovative models and technological methods that can fast-track the timeline of NGP product to market for our clients. Winclove, an innovative Dutch SME, is a leader in microbiota-management, which has been offering services in research, development and manufacturing of probiotic formulations for over 25 years. Winclove has been very successful in growing the company into a sustainable business with 73 FTE, growing 14% per annum on average. It provides its services to over 80 customers in 35 countries worldwide. As such, it has sold via its clients over 130 million daily dosages in 2018. Winclove aims to provide the NOVOBIOME platform as a B2B fee for service to dedicated innovative companies that are working on NGP-based LBPs. Winclove anticipates to generate €8M in turnover within the first 5 years of commercializing the NOVOBIOME platform. This SME-1 instrument project NOVOBIOME phase 1 enables Winclove to investigate the requirements to maximize the European commercialization

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVOBIOME-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVOBIOME-1" are provided by the European Opendata Portal: CORDIS opendata.